Clazosentan (Actelion).

Abstract

Clazosentan, an endothelin ETA antagonist, is under development by Actelion (formerly Axovan), under license from F Hoffman-La Roche, for the potential prevention of cerebral infarction and ischemia induced by cerebral vasospasm following subarachnoid hemorrhage. Results from the phase IIb portion of a phase IIb/III clinical study are expected in the first half of 2006.

• Authors: Dirk Uhlmann
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 3 Pg. 272-81 (Mar 2006) ISSN: 1472-4472 [Print] England
• PMID: 16555688 (Publication Type: Journal Article)

Chemical References

• Dioxanes
• Endothelin-1
• Pyridines
• Pyrimidines
• Sulfonamides
• Tetrazoles
• Vasoconstrictor Agents
• clazosentan

Topics

• Clinical Trials, Phase III as Topic
• Dioxanes (antagonists & inhibitors, therapeutic use)
• Endothelin-1 (antagonists & inhibitors)
• Humans
• Molecular Conformation
• Pyridines (antagonists & inhibitors, therapeutic use)
• Pyrimidines (antagonists & inhibitors, therapeutic use)
• Subarachnoid Hemorrhage (drug therapy)
• Sulfonamides (antagonists & inhibitors, therapeutic use)
• Tetrazoles (antagonists & inhibitors, therapeutic use)
• Vasoconstriction (drug effects)
• Vasoconstrictor Agents (chemistry, therapeutic use)
• Vasospasm, Intracranial (drug therapy)